Pluripotent embryonic stem cells (ESCs) self-renew or differentiate into all tissues of the developing embryo and cell-specification factors are necessary to balance gene expression. Here we delineate the function of the PHD-finger protein 5a (Phf5a) in ESC self-renewal and ascribe its role in regulating pluripotency, cellular reprogramming and myoblast specification. We demonstrate that Phf5a is essential for maintaining pluripotency, since depleted ESCs exhibit hallmarks of differentiation. Mechanistically, we attribute Phf5a function to the stabilization of the Paf1 transcriptional complex and control of RNA polymerase II elongation on pluripotency loci. Apart from an ESC-specific factor, we demonstrate that Phf5a controls differentiation of adult myoblasts. Our findings suggest a potent mode of regulation by Phf5a in stem cells, which directs their transcriptional programme, ultimately regulating maintenance of pluripotency and cellular reprogramming.
The remarkable cellular plasticity that defines ESCs is central towards their ability to differentiate into all somatic lineages and the germ line 1, 2 . Their unique identity is governed by regulation on multiple levels, ultimately orchestrating gene expression 3 . However, ESCs must readily alter their transcriptional programme to allow proper cell specification. Therefore, elucidating molecular mechanisms of cellular adaptation is paramount in understanding stem cell function. We have previously characterized several factors necessary for maintaining ESC self-renewal or initiating differentiation 4 . Using an RNAi-based screen we identified the poorly characterized PHDfinger protein 5a (Phf5a) as a potential modulator of pluripotency 4 . Phf5a is a small, highly conserved protein ( Supplementary Fig. 1a ) harbouring a characteristic PHD-fold 5 . Ectopic Phf5a was suggested to localize to the nucleus, postulated to associate with chromatin mediating transcription 5 . Deletion of Phf5a is lethal in yeast and knockdown in Caenorhabditis elegans results in aberrant organogenesis during early development 5, 6 , suggesting its importance for embryo formation and tissue morphogenesis 6 . However, its functional role in transcription regulation in mammals remains unexplored.
Modulation of gene expression is crucial for stem cell selfrenewal or cell specification. The Paf1 transcriptional complex (Paf1C) is central to these processes dictating RNA-PolII function and deposition of histone modifications 7, 8 . Paf1C plays important roles in development and is necessary for differentiation [9] [10] [11] ; however, details regarding its function in stem cells remain unknown. Here we demonstrate that Phf5a is a potent regulator of Paf1C stability and chromatin binding. Furthermore, we show that it is essential for ESC self-renewal, and cellular reprogramming and found that RNA-PolII elongation of pluripotency genes is defective after Phf5a depletion. Beyond its role in ESCs, we found Phf5a to regulate muscle specification, suggesting additional functions in adult stem cells. We conclude that Phf5a is crucial for regulating RNA elongation of genes controlling pluripotency and cell differentiation.
RESULTS

Phf5a depletion leads to loss of ESC pluripotency and inhibits reprogramming
To delineate the role of Phf5a in pluripotency, we investigated its expression levels during mouse ESC differentiation. We utilized the Supplementary Fig. 7 ). D0, day 0. (b) Histogram fluorescence-activated cell sorting (FACS) plots representing loss of GFP fluorescence in Nanog-GFP transcriptional reporter ESCs following knockdown with control shRNA (shControl) or Phf5a shRNA (shPhf5a). (c) Alkaline phosphatase staining of ESCs following knockdown with shControl or shPhf5a (two different hairpins). Scale bars, 100 µm.
(d) Heatmap of Affymetrix microarrays for differentially expressed genes of Nanog-GFP ESCs following knockdown with shControl or shPhf5a, respectively. Red, upregulated genes; blue, downregulated genes. Q value < 0.05. Fold change (log 2 ) > 1. 5 . (e,f) Bar graphs showing expression levels by qRT-PCR of Phf5a, pluripotency markers (e) and differentiation markers (f), respectively, following shPhf5a knockdown in ESCs. n = 6 biologically independent replicates (see Supplementary Table 5 ). Phf5a, Nanog, Pou5f1, Sox2, Zfp42 and Nr0b1: * * P = 0.0001. Gata6, Gata4, Nkx2-5, Sox1 and Meox1, * * P = 0.0001; Brachyury: NS, not significant; P = 0.5632, two-sided Student's t-test, values represent the mean ± s.d. (g) GO circle plot displaying gene-annotation enrichment analysis. Blue and red indicate downregulated or upregulated gene-associated GO terms, respectively, relative to the z score of the analysis. (h) GO chord plot displaying relationships between several representative downregulated and upregulated GO terms and associated genes. Distinct categories linked to pluripotent or differentiated cells cluster separately. FC, fold change. (i) Western blot analysis of pluripotency factors following CRISPR-Cas9-mediated Phf5a depletion in ESCs (unprocessed original scans of blots are shown in Supplementary Fig. 7 ).
Nanog-GFP (NG) reporter ESC line, a faithful indicator of selfrenewal 4, 12 . Phf5a expression, both at mRNA and protein levels, is high in pluripotent ESCs, but becomes rapidly downregulated following differentiation ( Fig. 1a and Supplementary Fig. 1b ). Consistent with a possible role in preserving self-renewal, knockdown of Phf5a led to a significant loss of Nanog-GFP fluorescence (Fig. 1b ). This was accompanied by morphological changes ( Supplementary Fig. 1c ), and cells exhibited considerably reduced alkaline phosphatase (AP) staining, an additional marker of pluripotency ( Fig. 1c ). Importantly, we did not observe increased levels of cell death or apoptosis following Phf5a knockdown ( Supplementary Fig. 1d,e ), suggesting that its loss leads to differentiation without effects on viability. We next determined the transcriptional response of Phf5a silencing by gene expression array analysis revealing two sets of genes significantly up-or downregulated ( Fig. 1d and Supplementary  Table 1 ). Changes in expression of selected genes were validated with qRT-PCR. Consistent with ESC differentiation, pluripotency markers were significantly downregulated, whereas lineage markers (a,b) Comparison of mass (a) and size (b) of teratomas generated in Severe combined immunodeficiency (SCID) mice following injection of doxycyclineinduced ESCs engineered to express shControl or shPhf5a cassettes from the Col1a1 locus. n = 4 biologically independent replicates (see Supplementary  Table 5 ). * * P = 0.001 two-sided Student's t-test, values represent the mean ± s.d. (c) Comparison of Phf5a transcript levels between differentiated fibroblasts and pluripotent stem cells by qRT-PCR. n = 4 biologically independent replicates (see Supplementary Table 5 ). ESCs: * * P = 0.0035, iPSCs: * * P = 0.0013, two-sided Student's t-test, values represent the mean ± s.d. (d) Western blot analysis of Phf5a protein in differentiated fibroblasts or pluripotent stem cells (unprocessed original scans of blots are shown in Supplementary Fig. 7) . (e,f) Alkaline phosphatase (AP) staining (e) and comparison of AP-positive ESC-like colony number (f), respectively, of reprogrammable OKSM MEFs on day 14 post-initial doxycycline induction following shPhf5a knockdown. n = 4 biologically independent replicates (see Supplementary Table 5 ). * * P = 0.001, two-sided Student's t-test, values represent the mean ± s.d.
were upregulated with the exception of several mesoderm markers ( Fig. 1e ,f). To further characterize gene expression profiles of Phf5adepleted ESCs, we performed RNA-seq followed by Gene Ontology (GO) and gene-annotation enrichment analysis 13 . Downregulated genes associated with GO terms related to stem cell function, such as stem cell maintenance, chromatin organization and cell division, whereas upregulated genes associated with GO terms related to early embryo development such as cell adhesion, cell cycle arrest and morphogenesis (Fig. 1g,h and Supplementary Fig. 1f ). Transcriptional profiling therefore strongly supports the notion that Phf5a loss triggers ESC differentiation. To validate our findings, we first ruled out potential off-target effects. Phf5a silencing using individual shRNAs, siRNAs and CRISPR-Cas9-mediated gRNAs, targeting distinct regions of its transcript, resulted in identical downregulation of pluripotency markers Oct4 and Nanog, as well as decreased AP staining ( Fig. 1i and Supplementary Fig. 1g -j). Examination of Phf5a levels in ESCs from different backgrounds revealed no significant differences during differentiation ( Supplementary Fig. 1k ,l). Finally, we engineered inducible knockdown ESC lines by introducing miR-30-shPhf5a cassettes in the Col1a1 locus of cells constitutively expressing the M2rtTA transactivator 14 , and were able to faithfully reproduce differentiation phenotypes following addition of doxycycline ( Supplementary Fig. 2a-d ). Using these lines, we also investigated the role of Phf5a in pluripotency in vivo. Injection of inducible ESCs in immunodeficient mice postinduction with doxycycline significantly inhibited the ability to form teratomas ( Fig. 2a,b ). Examination by haematoxylin and eosin stain as well as immunohistochemistry showed reduction of mesoderm markers compared with ectoderm or endoderm (Supplementary Fig. 2e -g). Specifically, we noticed apparent histological differences, including depletion of skeletal muscle formation, which we validated using desmin immunohistochemistry ( Supplementary Fig. 2g ). To further document defects in mesoderm differentiation, we examined in vitro differentiation towards the mesoderm lineage 15, 16 using the reporter ESC line Dppa4-RFP/Brachyury-GFP 17 . We found that shPhf5a depletion results in loss of self-renewal (Dppa4-RFP reduction), however, without an increase of mesoderm differentiation (Brachyury-GFP gain) ( Supplementary Fig. 2h ). Last, we were unable to detect upregulated Brachyury protein levels or additional mesoderm markers ( Supplementary Fig. 2i ,j). These results suggest that Phf5a loss results in failure of self-renewal maintenance while affecting lineage skewing, demonstrating its importance in stem cells.
These phenotypes prompted us to further investigate its role in pluripotency and cellular reprogramming. We compared Phf5a expression in pluripotent or differentiated cells and found that it correlated with the pluripotent state ( Fig. 2c,d ). Consistent with that, analysis of proliferation profiles in ESCs or primary mouse embryo fibroblasts (MEFs) following shPhf5a silencing resulted only in ESC self-renewal defects ( Supplementary Fig. 2k ,l). Finally, Phf5a overexpression during ESC differentiation maintained pluripotent marker expression ( Supplementary Fig. 2m ,n).
We reasoned that Phf5a expression might also regulate induced pluripotent stem cell (iPSC) formation. We silenced Phf5a in reprogrammable primary MEFs, engineered to express the Oct4, Klf4, Sox2 and c-Myc (OKSM) reprogramming cassette [18] [19] [20] and interrogated its effects 14 days post-induction of reprogramming factors. We observed that Phf5a loss resulted in a dramatic reduction of reprogrammed fibroblasts ( Fig. 2e and Supplementary  Fig. 2o ). We noticed a significant decrease in the absolute number of AP-positive ESC-like colonies ( Fig. 2f ), suggesting that Phf5a silencing leads to decreased efficiency of reprogramming. Last, we examined transgene-independent expression of endogenous markers of pluripotency 18 and found that Phf5a deficiency blocked their upregulation ( Supplementary Fig. 2p ). Collectively, we conclude that Phf5a is necessary for ESC self-renewal and efficient iPSC generation as its silencing results in aberrant initiation of differentiation and a block to reprogramming.
Phf5a interacts with the Paf1 complex
The impact of Phf5a knockdown on ESCs and iPSCs prompted us to investigate its functional role propagating pluripotency. We first explored its intracellular localization. We engineered inducible Phf5aexpressing or control ESC lines, fractionated cytoplasmic and nuclear extracts following doxycycline induction and confirmed a primarily nuclear localization in ESCs ( Supplementary Fig. 3a ). Immunofluorescence confirmed nuclear accumulation of Phf5a ( Supplementary  Fig. 3b ). Given its internal PHD-finger motif, we hypothesized a possible role in transcription and chromatin regulation.
To identify its molecular function we undertook an unbiased approach by purifying Phf5a from ESCs and analysing its interacting partners by mass spectrometry ( Fig. 3a and Supplementary Table 2 ). Among the top interacting proteins we found 3 out of 6 subunits of the Paf1 transcriptional complex (Paf1C). The mammalian Paf1C, which consists of the subunits Ctr9, Rtf1, Leo1, Paf1, Cdc73 and Wdr61, has been implicated in transcriptional regulation and deposition of histone modifications 7 . Since mass spectrometry suggested close association of Paf1C with Phf5a and since Paf1C depletion also results in ESC differentiation 21, 22 , we decided to further investigate this interaction.
Although we initially identified specific Paf1C subunits as Phf5a binding partners, we validated interactions with the entire complex ( Fig. 3b ). Similar to Phf5a, Paf1C subunits are downregulated during ESC differentiation ( Supplementary Fig. 3c ). We engineered inducible knock-in ESC lines expressing the subunits Cdc73 and Wdr61 and confirmed binding with Phf5a ( Supplementary Fig. 3d ). Furthermore, we validated Phf5a-Paf1C interactions using tandemaffinity purification ( Supplementary Fig. 3e ), as well as endogenous protein immunoprecipitations in ESCs ( Fig. 3c ). Importantly, we found that DNA or RNA does not mediate this interaction since it persists after extensive nuclease treatment ( Supplementary  Fig. 3f ). These results suggest a robust interaction between Phf5a and Paf1C.
We next attempted to specify whether distinct Paf1C subunits mediate this interaction. We in vitro translated Paf1, Cdc73 and Wdr61 subunits and interrogated binding to purified recombinant Phf5a. We observed interactions with Cdc73 and Wdr61 subunits but not Paf1 ( Fig. 3d ), suggesting that Phf5a binds to a subset of Paf1C subunits directly. Next, we performed glycerol gradient density sedimentation analysis from ESCs and identified that Phf5a forms high-molecularweight complexes and co-fractionates with Paf1C under native conditions ( Fig. 3e ). Furthermore, since Paf1C is implicated in transcriptional elongation, we confirmed Phf5a interaction with RNA-PolII ( Supplementary Fig. 3g ). Moreover, in density sedimentation analysis the elongating form of RNA-PolII co-sedimented with Phf5a and Paf1C (Fig. 3e ), indicating active engagement during transcription elongation. In contrast, we were unable to detect interaction with the initiation factor TFIID ( Supplementary Fig. 3e ), absent in elongating complexes, suggesting Phf5a association with PolII at specific transcription stages. These findings establish interaction of Phf5a with Paf1C and suggest its possible role in transcriptional regulation in ESCs.
Phf5a depletion leads to Paf1C destabilization and loss of binding to its target genes
The direct interaction between Phf5a and Paf1C together with differentiation phenotypes after knockdown suggested an intimate connection to Paf1C function. To explore this functional association, we first compared gene expression profiles of Phf5a-and Paf1-depleted ESCs and found similar gene expression patterns (Supplementary Fig. 4a and Supplementary Table 3 ). Since Phf5a was previously implicated in alternative exon recognition in malignant cells 23 , we also investigated whether shPhf5a or shPaf1 knockdown results in aberrant alternative splicing in ESCs. We used multivariate analysis of transcript splicing 24 , and found a small number of splicing differences, concluding that their loss does not result in overt changes in splicing patterns ( Supplementary Table 4 ).
We next studied Paf1C stability following loss of Phf5a. We reexamined Paf1C composition using density sedimentation analysis in the presence or absence of Phf5a. We found that Phf5a knockdown leads to Paf1C distribution towards lower molecular-weight fractions, indicating destabilization ( Supplementary Fig. 4b-e ). In contrast, other protein complexes, such as Swi/Snf and NELF, remain unaltered ( Supplementary Fig. 4f ). This suggested loss of interaction among Paf1C subunits and we confirmed significant decrease between subunit associations following Phf5a silencing (Fig. 4a ).
These findings suggested decreased Paf1C binding to target genes after Phf5a loss. We directly interrogated Paf1C occupancy in ESCs using Leo1, Cdc73 and Paf1 chromatin precipitation (ChIP)sequencing in the presence or absence of Phf5a. We identified ∼4,200 high-stringency targets of Paf1C in ESCs ( Fig. 4b) with Cdc73and Paf1-bound genes constituting subsets of Leo1-bound genes. We observed that Paf1C peaks virtually disappear following Phf5a silencing, supporting its critical role in complex function ( Fig. 4c,d ). We dissected peak localization and determined occupancy among promoters, UTRs, coding and intergenic regions. Consistent with regulation of active gene expression 25 , we noticed that Leo1 peaks fall mostly within gene bodies and promoters ( Fig. 4e ). Further dissection revealed that downregulated genes engage Leo1 mostly within gene bodies (42%), whereas upregulated genes utilize Leo1 mostly on promoters (47%) ( Supplementary Fig. 4g ). This suggests that Paf1C sub-complexes may differentially localize on their targets A R T I C L E S *
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(d) Paf1-complex subunits Paf1, Cdc73 and Wdr61 were cloned in HA-tag-expressing vectors and subjected to in vitro transcription and translation. Phf5a protein was expressed and purified from bacteria.
In vitro binding of HA-tagged subunits and Phf5a was interrogated by a pulldown assay using HA-immunoprecipitation and western blot analysis (unprocessed original scans of blots are shown in Supplementary  Fig. 7 ). (e) Phf5a interacting proteins from ESCs were subjected to glycerol gradient sedimentation followed by fractionation and western blot analysis resulting in overlapping distributions of Phf5a and Paf1complex subunits. A control analysis for GFP is shown in the lower panel (unprocessed original scans of blots are shown in Supplementary  Fig. 7 ).
to control gene expression. However, using gene-set enrichment analysis we found that Paf1 targets are enriched in pluripotency genes and correlate with ESC signatures (Fig. 4f ). These Paf1C targets include Pou5f1, Esrrb, Sall4, Prdm14 and other well-described pluripotency genes ( Fig. 4g ). Finally, to test direct Phf5a binding to the self-renewal network we engineered a Tet-inducible haemagglutinin (HA)-tagged Phf5a line and performed ChIP-seq using HA-epitope after doxycycline induction. Consistent with previous findings, we identified Phf5a binding to pluripotency genes such as Nanog, Pou5f1, Fbxo15, Esrrb, Tcf3, Prdm14, Sall4 and others ( Supplementary Fig. 4h ).
Loss of Phf5a leads to RNA-PolII promoter-proximal pausing
The Paf1C facilitates transcriptional elongation 26 and is required for maximal levels of Ser2-P-PolII (refs 27,28) . Since our studies suggest that Phf5a controls Paf1C binding on self-renewal genes, we hypothesized that its loss might lead to their aberrant elongation. We first investigated Ser2-P-PolII levels following Phf5a loss and found them significantly lower ( Fig. 5a and Supplementary Fig. 5a ). We next interrogated effects on RNA-PolII stalling and regulation of elongation. Pausing of activated RNA-PolII constitutes a rate-limiting step in gene expression and pause release is important for embryonic development 29, 30 and somatic cell reprogramming 31 . We profiled nascent RNAs using global-run-on sequencing (GRO-seq) 32 and calculated the elongation pausing index in ESCs following shPhf5a knockdown. We initially observed that downregulated genes were paused ( Fig. 5b ,c) in contrast to upregulated genes ( Fig. 5d ) signifying a difference between the two sets. We further dissected pausing ratios for multiple GO subsets. Downregulated categories exhibited significantly elevated promoter-proximal pausing compared with upregulated ones (Fig. 5e ). In addition, downregulated gene read density shows significant decrease within gene bodies ( Fig. 5f ). Similar to shPhf5a, shPaf1 knockdown leads to profound RNA-PolII pausing on downregulated genes ( Fig. 5g ) analogous to flavopiridol treatment 33 . In contrast, ESCs differentiated in the absence of LIF did not exhibit increased RNA-PolII stalling ( Supplementary Fig. 5b-d ), suggesting specific roles for Paf1C/Phf5a in maintenance of pluripotency. Indeed, we found that ∼50% of downregulated genes are direct ChIP-seq Paf1C targets and show promoter-proximal pausing after shPhf5a knockdown, compared with upregulated targets ( Supplementary Fig. 5e ).
To further study elongation dynamics we performed ChIPseq for initiating (Ser5-phosphorylated) and elongating (Ser2-phosphorylated) RNA-PolII in the presence or absence of Phf5a. We calculated the RNA-PolII pausing index 25 and found that Paf1C targets and self-renewal genes, such as Nanog Pou5f1, Sox2, Klf4 Fbxo15, Myc, Esrrb and others, exhibit significant stalling ( Fig. 5h ). We also found elevated levels of Ser5-RNA-PolII near gene promoters for related GO term genes, in contrast to decreased Ser2-RNA-PolII in their corresponding gene bodies ( Supplementary Fig. 5f ,g). Finally, we interrogated whether Phf5a affects histone modifications associated with Paf1C function 7 . We performed ChIPsequencing for H3K4me3, H3K79me2 and H3K36me3 in the presence or absence of Phf5a. We found its depletion negatively affected elongation-associated histone modifications H3K79me2 and H3K36me3 on Paf1C targets and self-renewal genes, but not the promoter-associated mark H3K4me3 (Fig. 6a ). H3K79me2 and H3K36me3 profiles revealed a pronounced loss from gene bodies after shPhf5a knockdown (Fig. 6b ). Dissection of H3K79me2 revealed that Paf1C targets have similar profiles to downregulated genes, compared with upregulated ones (Fig. 6c ). Last, we examined occupancy on pluripotency genes and found diminished H3K79me2 and H3K36me3 levels in their gene bodies, but not H3K4me3 levels on their promoters, compared with housekeeping genes (Fig. 6d ). These data suggest that Phf5a loss affects Paf1C functions including regulation of RNA-PolII elongation and histone mark occupancy.
Phf5a regulates myogenic differentiation
We next asked whether Phf5a functions specifically in ESCs or it controls differentiation in additional systems. Since Phf5a depletion results in aberrant mesoderm differentiation and muscle formation in teratomas, and Paf1 is also implicated in cardiomyocyte specification in zebrafish 10 , we decided to study Phf5a function in muscle. Myoblasts self-renew; however, in differentiation conditions, they commence myogenic programmes and fuse, forming elongated, multinucleated myotubes ( Supplementary Fig. 6a ). We initially depleted Paf1C subunits in C2C12 myoblasts and verified its role in myotube differentiation ( Supplementary Fig. 6b ). We then depleted Phf5a and found that it also compromises their ability to differentiate. We observed that myoblasts fail to upregulate the differentiation marker myosin heavy chain (MHC) ( Supplementary Fig. 6c,d ). Additionally, Phf5a silencing results in maintenance of Pax7, a marker of myoblast self-renewal ( Fig. 7a ). To support our findings in C2C12 cells, we generated a Tet-inducible RNAi mouse model by knocking-in individual shPhf5a hairpins in the Col1a1 locus of ESCs ( Fig. 7b ). We generated Rosa26 rtTA Col1a1 TRE shPhf5a mice and crossed them to EIIA-Cre mice to drive hairpin expression ( Fig. 7b ). We generated primary mouse myoblasts from these animals, and observed defects in myotube differentiation following Phf5a silencing ( Fig. 7c ). We observed upregulation of Phf5a and Paf1C during primary myoblast differentiation ( Supplementary Fig. 6e ) and were also able to mimic effects of RNAi depletion on myotube differentiation using CRISPR-Cas9 strategies (Fig. 7d,e and Supplementary Fig. 6f,g) . These results demonstrate that loss of Phf5a blocks myogenic differentiation.
To further investigate how Paf1C/Phf5a control mechanisms of muscle differentiation, we performed ChIP-sequencing for Leo1 in myoblasts and myotubes. We found an increased number of Leo1-bound genes during muscle differentiation from 700 genes in myoblasts, to more than 2,700 in myotubes (Fig. 7f ). GO analysis of Leo1-bound genes identified multiple chromatin-and transcriptionassociated GO terms in myoblasts, such as chromatin assembly, nucleosome organization and others, compared with muscle-specific GO terms in differentiated myotubes, such as actin organization, muscle development, muscle organization and myofibril assembly ( Supplementary Fig. 6h,i) . Examples for Leo1 binding include Hist1 cluster genes in myoblasts, Myog, Myo1c and Myom3 in myotubes and many others (Fig. 7g ).
Finally, we performed ChIP-sequencing in myotube differentiation after shPhf5a knockdown. We found that Leo1 binding was abolished from its myotube targets ( Fig. 7h and Supplementary Fig. 6j ). Interestingly, we identified ∼1,000 Leo1 targets after shPhf5a knockdown; however, almost none of them is associated with myogenic processes (Fig. 7h ). In addition, we performed GO analysis of Leo1 targets after shPhf5a knockdown and found genes associated with neurogenesis, instead of myogenesis ( Supplementary Fig. 6j ). Specifically, we identified neurological system process, cognition, sensory perception of smell, and sensory perception of chemical stimulus GO terms after shPhf5a knockdown ( Supplementary Fig. 6j ). We observed loss of Leo1 binding in specific myogenic genes, but gain in neurogenic ones such as olfactory, taste and neurotransmitter receptors, G-proteincoupled receptors, ion channels and many others (Fig. 7i ). Finally, to investigate whether Phf5a loss affects Paf1C stability we directly interrogated interactions among Paf1C subunits after its knockdown and found dissociation of the core subunits Leo1 and Cdc73, resulting in complex disruption (Fig. 7f ). In conclusion, these studies confirm that Phf5a is an essential regulator of myoblast differentiation and suggest that it stabilizes Paf1C in chromatin promoting myogenic programmes.
DISCUSSION
Since their early characterization, PHD-finger proteins were recognized as tethering molecules recruiting or stabilizing protein complexes [34] [35] [36] leading to tight regulation of gene expression 37 . Here we characterize in detail the functions of Phf5a in ESCs, iPSCs and myoblasts and attribute its requirement for self-renewal to the binding and stabilization of the Paf1C. We found that Phf5a depletion resulted in ESC differentiation and inhibition of cellular reprogramming. Phf5a and Paf1C associate strongly, are recruited on actively transcribed pluripotency genes and positively regulate RNA-PolII elongation.
Previous efforts to study Paf1C functions focused entirely on promoter occupancy using ChIP-on-chip assays 21 , or in relation to DNA methylation 38 . Our studies characterize how Phf5a affects elongation dynamics in self-renewing ESCs and we integrated a combination of approaches to elucidate its functions. First, we characterized promoter-proximal pausing ratios using nascent RNA profiling following Phf5a depletion. Second, utilizing RNA-PolII ChIPsequencing we calculated travelling ratios on pluripotency genes and Paf1C targets. Last, we determined how elongation-specific histone marks change in response to Paf1C alterations. Our results suggest that Phf5a directly regulates Paf1C stability, facilitating pause release and productive elongation of the self-renewal network. Elongation of upregulated genes in the absence of Paf1C is due to indirect effects. Direct Paf1C/Phf5a targets include master regulators of pluripotency, and it would be intriguing to further study mechanisms of Paf1C/Phf5a recruitment and possible cooperation with transcription factors 22 .
Furthermore, we found that Phf5a functions are not limited to ESCs. Using in vivo and in vitro models we demonstrated that Phf5a is essential for differentiation of myoblasts to myotubes. These functions are Paf1C-dependent as loss of Phf5a expression leads to significant decrease of Paf1C occupancy at myogenic genes and de novo targeting at neurogenic ones. These findings are consistent with Paf1C regulating cardiac specification and heart morphogenesis in zebrafish 10 and deregulation on muscle organ formation in Phf5a-depleted C. elegans 6 . Collectively, we conclude that Phf5a mediates Paf1C functions to orchestrate myogenic differentiation. Anti-Actin Anti-Phf5a Supplementary Fig. 7) .
Processes that balance self-renewal or cell specification can be deregulated in cancer. Paf1C can also act as an oncogene and its amplification or overexpression is implicated in tumour formation 8, 39 .
Although Paf1C stimulates transcriptional elongation in vitro and in vivo 7, 26, 40 , it was recently suggested to also suppress RNA-PolII transcription in cancer 41 . Our data suggest that Paf1C is active in ESCs, directly promoting elongation of pluripotency networks. However, Paf1C may function in a cell-type-specific manner influenced by chromatin accessibility.
Recent studies in human malignancies implicated Phf5a in endometrial cancer and glioblastoma 23, 42 . Although Phf5a is suggested to interact with ATP-dependent helicases and the U2 snRNP spliceosome 23, 43 , its silencing surprisingly affects exon recognition and splicing only in glioblastoma stem cells but not their normal counterpart neural stem cells 23 . Despite extensive sequencing studies, we did not find significant splicing defects in Phf5a-depleted ESCs, enforcing the notion that these are cell-type specific. It would be intriguing to speculate that splicing phenotypes are absent from non-malignant cells (ESCs and neural stem cells) but present in glioblastoma or other malignancies, opening the way to investigate this distinction as a potential vulnerability in cancer. It is interesting to interrogate whether aberrant Phf5a expression correlates with deregulated Paf1C functions in human disease, and since Phf5a loss inhibits proliferation of cancer cells 44 , its targeting might be an alternative therapeutic option.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper. Culture of C2C12 myoblasts, and myotube differentiation. C2C12 myoblast cells were cultured as described previously 46 . For differentiation, C2C12 cells were grown to confluence followed by culturing in differentiation media (DMEM supplemented with 2% horse serum) for 72 h or up to 120 h before analysis.
Immunofluorescence. ESCs expressing Flag-Phf5a or C2C12 cells were fixed with 4% formaldehyde in PBS for 20 min at room temperature, washed once with PBS and permeabilized for 20 min at room temperature using Block Solution (5% normal goat serum, 0.1% Triton X-100 in PBS). Cells were incubated overnight at 4 • C with Flag antibody (1:500), Desmin (1:500) or MHC serum (1:500) in Block Solution, washed three times with PBS, incubated for 1 h at room temperature with 1:1,000 secondary rabbit anti-mouse Alexa594-conjugated antibody in Block Solution and DAPI.
Animal experiments. Female C57BL/6 mice (6-8 weeks old) were obtained from the National Cancer Institute. For teratoma assays, non-obese diabetic/severe combined immunodeficient NOD/MrkBomTac-Prkdc scid (NOD-SCID) mice were obtained from Taconic. KH2 ESCs (10 6 ) engineered to express inducible shControl or shPhf5a hairpins were injected subcutaneously into NOD-SCID mice, were under 0.1 mg doxycycline diet throughout the course of the assay and were euthanized 3 weeks after injection when tumours were collected. Tumours were fixed in formalin followed by imbedding in paraffin, sectioned and stained for histological analysis with haematoxylin and eosin or immunohistochemistry stains following standard procedures. For generation of Tet-inducible knockdown animals, Rosa26 rtTA Col1a1 TRE shPhf5a-targeted ESCs were purchased from Mirimus. Mice were generated by injection into tetraploid blastocysts at the NYU Medical Center Rodent Genetic Engineering Core. Engineered mice were crossed to EIIA-Cre recombinase mice to drive Rosa26 rtTA expression. For in vivo Col1a1 TRE shPhf5a cassette expression, mice were placed on 0.1 mg doxycycline diet. Isolation and growth of primary myoblasts was performed as described previously 47 . Briefly, neonatal mice were euthanized and limb muscle was dissected from skin and bones. Primary myoblasts were isolated in mincing and incubation of muscle in collagenase/dispase/CaCl 2 solution followed by incubation in a 5% CO 2 incubator using F-10-based primary myoblast growth medium. Mice were housed in specific pathogen-free conditions at the Skirball Institute animal facility. For animal experiments, no statistical method was used to predetermine sample size. Furthermore, the experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. All animal experiments were performed in accordance with protocols approved by the New York University Institutional Animal Care and Use Committee.
CRISPR-Cas9 editing.
For CRISPR-Cas9 editing, Control-and Phf5a-targeting and repair template vectors were purchased from Santa Cruz (sc-418922, sc-427066, sc-427066-HDR) and were transfected in ESCs or C2C12 cells using Lipofectamine 2000 (Life Technologies) according to the manufacturer's manual.
Engineering of inducible ESCs expressing tagged proteins or shRNAs.
For inducible expression, cDNA was prepared (High-Capacity RNA-to-cDNA Kit, Applied Biosystems). Open reading frames (ORF) were cloned into the Tet-operated vector pINTA, bearing N-terminal Flag/Strep-TagII (F/S) tandem tags 48 (gift from R. Bonasio, University of Pennsylvania, USA). Vectors were nucleoporatated (Amaxa) into KH2 ESCs 19, 49 . ESCs were selected with 50 µg ml −1 Zeocin (Invitrogen) for 7 days.
For inducible knockdown, miR-30 hairpins were cloned into a modified pColTGM vector 14 targeting the Col1a1 locus. Vectors were electroporated with pCAGS-FlpE recombinase in KH2 ESCs and were selected with hygromycin 140 µg ml −1 for 10 days.
shControl: 5 -TGCTGTTGACAGTGAGCGCAGGAATTATAATGCTTATCT  ATAGTGAAGCCACAGATGTATAGATAAGCATTATAATTCCTATGCCTAC  TGCCTCGGAA-3  shPhf5a: 5 -TGCTGTTGACAGTGAGCGACTATCGGAAGACTGTGTGAA  ATAGTGAAGCCACAGATGTATTTCACACAGTCTTCCGATAGCTGCCTAC  TGCCTCGGA-3 Antibody dilutions, western blotting and immunoprecipitations. Antibodies were used according to the manufacturer's specifications. For western blots, cells were lysed in lysis buffer (100 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% Triton X-100) supplemented with Complete Mini protease inhibitors (Roche), 10 mM NaF (Sigma) and 1 mM Na 3 VO 4 (Sigma). For immunoprecipitation (IP), 1 mg of precleared cell lysate was incubated overnight with each antibody or IgG control (sc-2027 Santa Cruz), and bound to Protein-A Sepharose beads (Invitrogen) at 4 • C. Beads were washed four times with 1 ml lysis buffer. Antibodies used were the following: Nanog (1:10,000 A300-397A, Bethyl), Oct-3/4 (1:5,000 sc-5279, Santa Cruz), actin (1:10,000 C4, Millipore), Flag (1:10,000 M2, Sigma), HA (1:5,000 ab-9110, Abcam) Phf5a (1:500 15554-1-AP, ProteinTech), Paf1 (1:1,000 A300-173A, Bethyl for IP, A300-172A, Bethyl for WB and purified rabbit antibody for ChIP 50 ), Cdc73 (1:1,000 A300-701, Bethyl), Ctr9 (1:1,000 A301-395A, Bethyl), Leo1 (1:1,000 A300-175A, Bethyl), Rtf1 (1:1,000 A300-179A, Bethyl), Wdr61 (Ski8) (1:500 pAB-012-150, Diagenode), caspase-3 (1:1,000 9662, Cell Signalling), GFP (1:5,000 sc-9996, Santa Cruz), RNA-PolII (1:1,000 sc-899, Santa Cruz), Ser2-phospho-RNA-PolII (1:1,000 clone 3E10, Active Motif), Ser5-phospho-RNA-PolII (1:1,000 ab5131, Abcam), TFIID (1:1,000 sc273 X, Santa Cruz), α-tubulin (1:10,000 sc-53029, Santa Cruz), lamin B (1:1,000 sc-6217, Santa Cruz), Pax7 (1:500 sc-81975, Santa Cruz), NELF-A (1:1,000 A301-910A, Bethyl), Brachyury (1:500 ab20680, Abcam), Desmin (1:1,000 ab32362, Abcam), Nestin (1:1,000 MAB353, clone rat-401, EMD Millipore), H3K4me3 (1:1,000 07-473, Millipore), H3K79me2 (1:1,000 39143, Active Motif), H3K36me3 (1:1,000 ab9050, Abcam). Serum against myosin heavy chain (MHC, gift from B. Dynlacht, NYU School of Medicine, USA) was used at 1:10,000. For western blots, antibodies were used in 5% milk in TBS-T, unless otherwise noted. Secondary horseradish peroxidase (HRP)-conjugated antibodies (GE Healthcare) were used in 5% milk in TBS-T. For immunoprecipitations, rabbit IgG Trueblot (1:5,000 18-8816-31, Rockland) or mouse IgG Veriblot (1:5,000 ab131368, Abcam) secondary HRP-conjugated antibodies were used.
Purification of tagged proteins and mass spectrometry. Targeted ESCs (5 × 10 7 ) were induced with 2 µg ml −1 doxycycline (Sigma) for 3 days and treated with 10 µM MG132 (Peptides International) for 3 h. Pellets were resuspended in lysis buffer (100 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 2 mM MgCl 2 ) supplemented with Complete Mini protease inhibitors (Roche), 10 mM N -ethylmaleimide (Sigma), 10 mM NaF (Sigma), 1 mM Na 3 VO 4 (Sigma) and 250 units of Benzonase nuclease (Novagen), and passed 8 times through a 25 and 5/8 gauge syringe. Protein purification was performed as described before 48 . Beads were eluted with 5 ml elution buffer (Buffer E, IBA) and concentrated with Amicon Ultra centrifugal filter units, 10,000 MW cutoff, (Millipore) to 200 µl. For tandemaffinity purification, elutions were bound to 50 µl Flag magnetic beads, washed with 1× Buffer E (IBA), and boiled in SDS-loading buffer. For cytoplasmic and nuclear fractionation, 1 × 10 7 KH2 ESCs were lysed as above and cytoplasmic and nuclear extracts were prepared as described previously using a glass homogenizer 51 . For mass spectrometry, peptides were analysed by LC-MS/MS on an Orbitrap Velos MS. The MS/MS spectra were searched against the NCBI database using a local MASCOT search engine (V.2.3). At least two peptides were identified for each protein (false discovery rate <0.01%) with a confidence interval no less than 95%.
Glycerol gradient density sedimentation analysis. Targeted ESCs (5 × 10 7 ) were induced, lysed and tagged proteins were purified as above and concentrated to a final volume of 500 µl. Glycerol gradients (15-35%) were prepared using BIOCOMP Gradient Master in 4.5 ml open-top tubes (Beckman) and fractions were prepared as described before using TCA precipitation 52 . ChIP-seq and library preparation. ChIP experiments were performed as described previously 55, 59 . Antibodies coupled to magnetic beads were added to precleared chromatin and incubated for 12-16 h. Beads were washed and eluted according to protocol. ChIP-Seq libraries for Paf1C components, PolII samples and histone marks were prepared using the Illumina TruSeq system, including end repair, A-tailing, adaptor ligation and PCR amplification. AMPure XP beads (Beckman Coulter, A63880) were used for DNA cleaning in each step of the process. Raw images generated by Illumina HiSeq2000 using default parameters were processed by CASAVA to remove the first and last bases and then they were used to generate sequence reads in fastq format. Reads were aligned to the mm10 mouse genome using Bowtie with the standard parameters (except for -m 1 to report only unique alignments). MACS version 1.4.2 (ref. 54) was used to perform peak calling using the parameter values listed below.
In the case of ChIP-Seq experiments for Paf1C components and Phf5a, MACS v1.4.2 was used and the parameter values were: -nomodel, -shiftsize=120, -slocal 5000, -llocal 50000, −P 10 −4 .
In the case of polymerase and histone ChIP-Seq experiments, MACS v.2.0 was used with the following parameter values: (a) -nomodel, (b) -broad, (c) -shiftsize=200, (d) -q 0.05.
All PolII and histone ChIP-Seq experiments were performed in triplicates and peaks present at least in two out of the three triplicates were used for downstream analysis. The files with the aligned reads were converted to wig format using GenomicTools 55 and then to bigwig format using the corresponding UCSC tool.
Peak characterization. Peaks were assigned to the following categories based on their genome-wide distribution: Upstream: this category includes all peaks that fall within 1-3 kb upstream of the transcription start site (TSS), Promoter: it includes all peaks that fall within 1 kb upstream of the TSS, Gene body: it includes all peaks that fall within the 5 UTR, the coding region of genes and the 3 UTR, Downstream: it includes all peaks that fall within 3 kb from the transcription end site (TES), Distal Intergenic: All the peaks that fall within the remaining genomic loci. The peak characterization was performed using ChIPSeeker 60 and custom in-house scripts.
Calculation of PolII pausing index. The calculation of PollII pausing index was performed as described previously 25 . Specifically, the PolII densities were initially calculated as reads per kilobase per million 61 to normalize for region length and number of reads. The initiating region was defined as the area between 30 bp upstream of the TSS to 300 bp after the TSS, while the elongating region was from +300 bp to the end of the gene. We calculated the PolII pausing index by dividing the PolII densities for the initiating region versus the elongating region. We used Wilcoxon's non-parametric test to compare the distributions of the fold-changes (log 2 scale) in the pausing index in the control (shControl) and the samples, where either Phf5a (shPhf5a) or Paf1 (shPaf1) were downregulated.
Gene-set enrichment analysis.
For GSEA analysis, the online version of the GSEA tool was used 62 . The peaks that were identified as significant after peak calling were ranked according to peak score (from highest to lowest) and they were used as input for GSEA. MSigDB v5.0 (updated in April 2015) was used for GSEA.
Gene ontology. Gene ontology (GO) analysis was performed on the basis of ChIP-Seq data and gene expression data by using the DAVID tool v6.7 (https://david.ncifcrf.gov). Visualization of the GO results was performed using the R package GOplot 13 . The reported z-score was calculated as described in GOplot and shows the trend (increasing/decreasing) of the corresponding GO category in terms of gene expression.
Statistics and reproducibility.
Sample sizes and reproducibility for each figure are denoted in the figure legends. Unless otherwise noted, data are representative of at least three biologically independent experiments. For mouse experiments, no statistical method was used to predetermine sample size. Furthermore, the experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Statistical significance between conditions was assessed by two-tailed Student's t-tests. Error bars represent s.d., and significance between conditions is denoted. Raw data from independent replicate experiments can be found in the Statistics Source Data (Supplementary Table 5 ). 
Primary accessions. Gene Expression Omnibus (GEO) GSE63974.
Data availability. The next-generation sequencing data that support the findings of this study in Figs 1 and 4-7 have been deposited in the Gene Expression Omnibus (GEO) database under the accession code GSE63974. Statistics source data have been provided as Supplementary Table 5 . All other data supporting the findings of this study are available from the corresponding author on request. 
